BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 30
• 31

• Genetown

  Aeglea BioTherapeutics to Participate in Upcoming November Investor Conferences

  Aeglea BioTherapeutics, Inc. (“Aeglea”) (Nasdaq: AGLE), a biotechnology company advancing a pipeline of antibody therapeutics with the potential to transform the treatment of inflammatory bowel disease (“IBD”), today announced that management will participate in the following investor conferences.

  October 30, 2023

   · 

  1 min read
• Job Trends

  Bristol Myers Squibb Prices $4.5 Billion of Senior Unsecured Notes

  Bristol Myers Squibb (NYSE: BMY) today announced that it has priced a public offering (the “Offering”) of senior unsecured notes in a combined aggregate principal amount of $4.5 billion (collectively, the “Notes”).

  October 30, 2023

   · 

  4 min read
• Genetown

  iNtRON, Executes Evaluation License and Option Agreement for SAL200

  iNtRON Biotechnology has announced that they have signed an “EVALUATION LICENSE AND OPTION AGREEMENT” with Basilea Pharmaceutica Ltd, Allschwil, granting Basilea the option to enter into an exclusive license agreement for the antibacterial bio-drug SAL200.

  October 30, 2023

   · 

  3 min read